Skip to main content
Premium Trial:

Request an Annual Quote

Decode Shares Sink 11.7 Percent On Higher Q1 Loss

NEW YORK, May 2 (GenomeWeb News) - Shares in Decode Genetics were down 11.65 percent, or $.89, at $6.75 in mid-afternoon trading after the company said first-quarter losses swelled 20 percent year over year.

 

As GenomeWeb News reported this morning, Decode said total revenues for the three months ended March 31 increased approximately 6-percent though net loss swelled to $20.3 million from $16.9 million in the year-ago period.

 

Decode attributed the increase to higher R&D costs related to clinical trials and preclinical development work in the company's lead drug-development programs.

The Scan

Science Confidence Boost

The New York Times reports that a new poll finds trust in science and scientists has increased with the COVID-19 pandemic.

Appeal and Funds

Some grant applications denied funding due to an Australian Research Council rule change have now been funded following an appeal, the Guardian reports.

Surveillance for Variants

Vox writes that the detection of the Omicron SARS-CoV-2 variant highlights the need for improved viral genomic surveillance.

Nature Papers Examine Taxonomic Gaps in Plant Sequencing, SARS-CoV-2-Human Interactome

In Nature this week: plant genome sequencing dominated by affluent countries, and more.